Article Details

Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic ...

Retrieved on: 2021-02-26 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic .... View article details on hiswai:

Excerpt

Artiva's pipeline includes AB-101, an ADCC enhancer NK-cell therapy for use in combination with monoclonal antibodies or innate-cell engagers.

Article found on: www.oaoa.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up